MACH7 TECHNOLOGIES LIMITED — Capital/Financing Update 2016

Sep 5, 2016

6 September 2016

==> picture [612 x 89] intentionally omitted <==

ASX Announcement

Mach7 Technologies Completes Major Implementation in Qatar

• Implementation phase complete at out-patient clinic of innovative, all-digital academic medical and research centre

• Minimum contract value of A$2 million plus ongoing annual support

• Mach7 contracted to provide additional workflow solutions for deployment later this year

Melbourne, Australia; 6 September 2016: Mach7 Technologies Limited ( Mach7 or the Company ) (ASX: M7T ), a recognised leader in the global enterprise imaging market, today announced the successful implementation of Mach7 Enterprise Imaging Platform (EIP) at Sidra Medical and Research Centre (Sidra) in Doha, Qatar.

Sidra Medical and Research Centre is a world-class, all-digital hospital for women and children. Sidra features a main hospital building and a separate outpatient clinic. The main hospital will initially have 400 beds with infrastructure to expand to 550 beds. Sidra opened its Outpatient Clinic in May 2016 with the launch of three clinics; Dermatology, Paediatric General Surgery Consultation and Obstetrics. These clinics are supported by radiology, pathology, pharmacy and laboratory facilities. The Sidra Outpatient Clinic offers outpatient services for women and children through a referral based system in partnership with other healthcare providers in Qatar. More clinics and services will be rolled out over the course of 2016.

Mach7 was engaged by Philips Medical Systems as a sub-contractor on the project whereby Mach7 EIP will manage all imaging; radiology and non-radiology clinical media. Sidra is prioritising multiple use-cases for the platform across all specialties to include aggregation and sharing of imaging, video, pathology results, and beyond.

With implementation of Mach7 EIP now complete at the Outpatient Clinic, Mach7 expects to recognise US$1.2 million (A$1.6 million) as revenue in the current financial year. In addition to this revenue, Mach7 will earn an annual support fee of between US$130,000 and US$200,000, adding to its growing annuity of support fee revenue. Mach7 has also been engaged to provide additional workflow solutions for deployment later this year.

-ENDS

==> picture [612 x 123] intentionally omitted <==

ASX Announcement

6 September 2016

==> picture [612 x 89] intentionally omitted <==

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimised vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com.

Mach7’s wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical’s innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au

Contacts:

Albert Liong Jenni Pilcher CEO CEO Australia, CFO +1 650 743 0167 (U.S.) +61 3 9646 2222 (Australia) albert.liong@mach7t.com jenni.pilcher@mach7t.com

Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com

==> picture [612 x 123] intentionally omitted <==